<DOC>
	<DOCNO>NCT00001576</DOCNO>
	<brief_summary>Patients unresectable metastatic colorectal cancer confine liver undergo 1 hour hyperthermic isolate hepatic perfusion ( IHP ) escalate dose melphalan . Postoperatively , patient treat hepatic arterial infusion floxuridine ( FUDR ) , 0.2 mg/kg/day leucovorin ( LV ) , 15 mg/M2/day 2-week continuous infusion regimen . Hepatic systemic toxicity , response treatment , duration response , survival follow .</brief_summary>
	<brief_title>A Phase I Study Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed Postoperative Hepatic Arterial Floxuridine Leucovorin Metastatic Unresectable Colorectal Cancers Liver</brief_title>
	<detailed_description>Patients unresectable metastatic colorectal cancer confine liver undergo 1 hour hyperthermic isolate hepatic perfusion ( IHP ) escalate dose melphalan . Postoperatively , patient treat hepatic arterial infusion floxuridine ( FUDR ) , 0.2 mg/kg/day leucovorin ( LV ) , 15 mg/M ( 2 ) /day 2-week continuous infusion regimen . Hepatic systemic toxicity , response treatment , duration response , survival follow .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Floxuridine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Histologically cytologically proven measurable metastatic colorectal cancer limit parenchyma liver evidence unresectable extrahepatic disease preoperative radiological study . Limited resectable extrahepatic disease acceptable . Patients must previously treat intrahepatic artery infusional therapy use FUDR . Patients mush chemotherapy , radiotherapy biologic therapy malignancy month prior liver perfusion must recover side effect . Patients must ECOG performance standard 0 , 1 2 day prior treatment . Patients must adequate hepatic function evidence bilirubin le 2.0 PT PTT within 12 second upper normal limit . Patients must biopsy proven cirrhosis evidence significant portal hypertension history , endoscopy , radiologic study . Patients must history congestive heart failure LVEF le 40 % . Patients must COPD chronic pulmonary disease PFT 's less 50 % predicted age . Patients must 18 year age old . Patients must platelet count great 100,000 Hct great 27.0 , white blood count great 3000/micro liter , creatinine le equal 1.5 creatinine clearance great 60 ml/min . Patients must pregnant nursing . Patients must take immunosuppressive drug chronic anticoagulation . Patients must active infection . Patients must severe allergic reaction iodine contrast control premedication antihistamine steroid . Patients must HIV disease . Patients must aware neoplastic nature his/her illness , experimental nature therapy , alternative treatment , potential benefit , risk . The patient must willing sign inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2002</verification_date>
	<keyword>Regional Therapy</keyword>
	<keyword>Organ Perfusion</keyword>
	<keyword>Metastases</keyword>
	<keyword>Hyperthermia</keyword>
</DOC>